{"nctId":"NCT02192502","briefTitle":"Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients","startDateStruct":{"date":"2015-03","type":"ACTUAL"},"conditions":["Postoperative Kidney Injury"],"count":149,"armGroups":[{"label":"HES 130/0.4 (Voluven)","type":"EXPERIMENTAL","interventionNames":["Drug: HES 130/0.4 (Voluven)"]},{"label":"human albumin 5%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: human albumin 5%"]}],"interventions":[{"name":"human albumin 5%","otherNames":[]},{"name":"HES 130/0.4 (Voluven)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 50 - 85 years old\n* Scheduled for elective aortic valve replacement with or without coronary artery bypass grafting with or without additional minor surgical procedure.\n* Written, informed consent for participation in this investigation.\n\nExclusion Criteria:\n\n* Patients with renal failure with oliguria or anuria not related to hypovolemia.\n* Patients receiving dialysis.\n* Patients with preoperative renal insufficiency (Creatinine \\> 1.6 mg/dL)\n* Anticipated deep hypothermic circulatory arrest\n* Known hypersensitivity or allergy to hydroxyethyl starch or the excipients of hydroxyethyl starch\n* Clinical conditions with volume overload (e.g., patients in pulmonary edema or congestive heart failure)\n* Patients with severe hypernatremia or severe hyperchloremia\n* Patients with intracranial bleeding\n* Pregnant or breast feeding women\n* Critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy, (e.g. patients who are hospitalized in the intensive care unit prior to surgery)\n* Severe liver disease\n* Pre-existing coagulation or bleeding disorders\n* Any contraindications to proposed interventions.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) [Time Frame: 24 Hours After Surgery] [Designated as Safety Issue: Yes]","description":"To assess the safety of HES 130/0.4 (Voluven) versus albumin 5% on renal function we will measure urinary concentrations of neutrophil gelatinase-associated lipocalin (NGAL), an important marker of renal function, measured at baseline (following anesthetic induction and prior to surgical incision), at one hour of arrival to intensive care unit (ICU), at 24 hours following completion of surgery.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Kidney Function","description":"Postoperative kidney dysfunction using RIFLE diagnostic criteria was also assessed. Patients were assessed for risk for kidney dysfunction (RIFLE-R), injury to the kidney (RIFLE-I), failure of kidney function (RIFLE-F) using criteria based on only peak serum creatinine concentrations within the first seven postoperative days. Due to too few events, this outcome was redefined to risk (or worse) vs. no risk for this analysis.\n\nRIFLE classification criteria is listed below:\n\nRisk (RIFLE-R) Increase in serum creatinine x 1.5 from baseline Injury (RIFLE-I) Increase in serum creatinine x 2 from baseline Failure (RIFLE-F) Increase in serum creatinine x 3 from baseline Loss (RIFLE-L) Complete loss of kidney function \\> 4 weeks End stage (RIFLE-E) End-stage kidney failure \\> 3 months","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Postop Urine IL-18","description":"Postop Urine IL-18 (interleukin-18) measured at 1 h of arrival to ICU","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Postop Urine IL-18","description":"Postoperative urine IL-18 (interleukin-18) measured at 24 hours after surgery","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"POST_HOC","title":"Kidney Function","description":"kidney injury using RIFLE criteria based on both peak creatinine levels and urine output, as recommended by Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group\n\nRIFLE classification criteria is listed below:\n\nRisk (RIFLE-R) Increase in serum creatinine x 1.5 from baseline urine output \\< 0.5 mL/kg/hr for more than 6 hrs Injury (RIFLE-I) Increase in serum creatinine x 2 from baseline urine output \\< 0.5 mL/kg/hr for more than 12 hrs Failure (RIFLE-F) Increase in serum creatinine x 3 from baseline urine output \\< 0.3 mL/kg/hr for 24 hrs or anuria for 12 hrs Loss (RIFLE-L) Complete loss of kidney function \\> 4 weeks End stage (RIFLE-E) End-stage kidney failure \\> 3 months","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":69},"commonTop":[]}}}